Marker Therapeutics, Inc.
MRKR
$0.88
-$0.04-3.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 146.69% | -84.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 146.69% | -84.50% | |||
| Cost of Revenue | 33.22% | -38.35% | |||
| Gross Profit | -19.01% | 1.70% | |||
| SG&A Expenses | -30.97% | 33.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.71% | -26.31% | |||
| Operating Income | -2.54% | -7.62% | |||
| Income Before Tax | 9.68% | -17.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.68% | -15.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.68% | -15.86% | |||
| EBIT | -2.54% | -7.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 28.13% | 4.28% | |||
| Normalized Basic EPS | 19.98% | 12.87% | |||
| EPS Diluted | 27.55% | 4.28% | |||
| Normalized Diluted EPS | 19.98% | 12.87% | |||
| Average Basic Shares Outstanding | 25.67% | 21.01% | |||
| Average Diluted Shares Outstanding | 25.67% | 21.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||